Logotype for Biodesix Inc

Biodesix (BDSX) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Biodesix Inc

Q3 2026 earnings summary

5 Nov, 2026

Executive summary

  • Q3 revenue was $24.041M, up 10% YoY; Diagnostic Tests revenue rose 16% and test volume increased 24% to 19,400. Gross margin held at 81%.

  • Growth fell below expectations due to sales execution, primary-care seasonality and delayed Development Services projects; management described these as execution and timing issues rather than weaker demand or market opportunity.

Financial highlights

  • Q3 net loss was $8.032M versus $8.716M; Adjusted EBITDA loss was $3.9M, improving 16% YoY.

  • Q3 operating loss was $6.112M versus $7.051M; 9M operating loss was $17.701M versus $25.906M.

  • 9M revenue was $76.457M versus $59.744M; 9M net loss was $23.098M versus $31.285M.

  • Operating expenses excluding direct costs and expenses were $25.5M, up 3% YoY and down 7% QoQ.

  • Q3 diluted loss per share was $0.75 versus $1.16; 9M diluted loss per share was $2.26 versus $4.24.

Outlook and guidance

  • FY2026 revenue guidance is $101M–$103M, with the midpoint implying ~15% growth over 2025; outlook reflects Q3 results, sales-team expansion timing and Development Services contract execution and revenue recognition.

  • Gross margin is expected to be ~80%, with continued progress toward profitability.

  • Q4 Development Services revenue is expected to be similar to Q3 at ~$1M; delayed projects are expected to move into 2027.

  • Early Q4 trends included accelerating new-customer acquisition and broader physician engagement; October was the strongest month of new physician acquisition this year.

  • Sales representatives numbered ~110, with ~115 expected by year-end; hiring cadence is expected to return to six to eight representatives per quarter.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Biodesix